Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec;63(12):1424-1432.
doi: 10.1111/ped.14706. Epub 2021 Oct 20.

Factors and glucocorticoid usage affecting the prognosis of systemic juvenile idiopathic arthritis

Ayşenur Paç Kısaarslan  1 , Sümeyra Özdemir Çiçek  1 , Nihal Şahin  1 , Merve Başol  2 , Şeyda Doğantan  1 , Sema Nur Taşkın  1 , Muammer Hakan Poyrazoğlu  1
Affiliations

Factors and glucocorticoid usage affecting the prognosis of systemic juvenile idiopathic arthritis

Ayşenur Paç Kısaarslan et al. Pediatr Int. 2021 Dec.

Abstract

Background: The rate of glucocorticoid (GC) use is significantly higher in systemic juvenile idiopathic arthritis (SJIA) than other juvenile idiopathic arthritis subtypes. There is no consensus on the duration and dosage of GC treatment. We aimed to investigate the risk factors for a polyphasic / persistent disease course and the effect of dose and duration of GC treatment on SJIA prognosis.

Methods: Forty-two patients who were diagnosed with SJIA, and for whom the duration of disease was longer than 2 years, were included. Patients were divided into monophasic and others (polyphasic / persistent disease course). Risk factors for polyphasic / persistent disease course, which were clinical and laboratory findings regarding the patients, treatment options, dose, and duration of GCs, were evaluated for the first active disease periods and for all flares in the entire disease course.

Results: Of the 42 SJIA patients, 21 had monophasic, and 21 had polyphasic / persistent disease. Cumulative dosages and durations of glucocorticoid treatment were similar in the two groups at the first flare (odds ratio (OR): 1.032 P: 0.671; OR:1,113 P: 0.115). Durations of the first active disease period were longer in the polyphasic / persistent group (OR:1.275, P: 0.01). Active disease duration cut-off values of 1.5 months with sensitivity 85.7%, specificity 52.4% were observed on receiver operating characteristic curve analysis. The presence of hepatosplenomegaly at first flare was detected as an independent risk factor of polyphasic/persistent disease by multivariate analysis included both dosage and duration of a steroid (hazard ratio (HR): 4.129, P: 0.034), (HR: 3.992, P: 0.038). Multivariate recurrent events survival analysis determined ALT levels as a risk factor affecting polyphasic / persistent disease (HR: 0.986, P: 0.037).

Conclusions: Glucocorticoid dose and duration did not affect the active disease periods and disease course in SJIA. An active disease period longer than 1.5 months, presentation of hepatosplenomegaly at the initial disease course, and high ALT levels at the recurrences should warn physicians of polyphasic / persistent disease.

Keywords: factors; glucocorticoids; prognosis; systemic JIA.

PubMed Disclaimer

References

    1. Petty RE, Southwood TR, Manners P et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 2004; 31: 390-2.
    1. Kumar S. Systemic juvenile idiopathic arthritis: diagnosis and management. Indian J. Pediatr. 2016; 83: 322-7.
    1. Cimaz R. Systemic-onset juvenile idiopathic arthritis. Autoimmun. Rev. 2016; 15: 931-4.
    1. Ringold S, Weiss PF, Beukelman T et al. 2013 update of the2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 2013; 65 (10): 2499-512.
    1. Ilowite NT, Sandborg CI, Feldman BM et al. Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology. Pediatr. Rheumatol. Online J. 2012; 10: 31.

Substances

LinkOut - more resources